Unbiased Analysis of Today's Healthcare Issues

Archive for the 'Pharmaceuticals' Category

Can physicians affect medication adherence?

According to a recent study by Koulayev, Simeonova, and Skipper (2016) using data from Denmark, the answer is ‘yes’. Non-compliance with medication therapy remains an unsolved and expensive problem for healthcare systems around the world, yet we know little about the factors that affect a patient’s decision to follow treatment recommendations. In particular, there is […]

Read the rest of this entry »

Can long acting injectables save money?

Patients with serious mental illnesses such as schizophrenia often struggle with medication adherence, due to lack of insight into their disease, medication side effects, forgetfulness, and a variety of other factors.  One solution to this problem is to use long-acting injectables or LAIs.  Whereas most antipsychotics are oral medications, LAIs are typically injectables that you need to […]

Read the rest of this entry »

Will value-based pricing be coming to the U.S.?

The answer may be yes.  One of the big inpediments to value-based pricing of pharmaceuticals was that any discount given to any single organization based on outcomes needed to be reflected in the Medicaid price.  Since outcomes are subject to random noise, there will inevitably be health plans that end up getting a low price due to worse than expected […]

Read the rest of this entry »

Sounds like a good idea?

Kaiser’s family of website has some interesting posts of late.  The Kaiser Family Foundation presents 10 Essential Facts about Medicare Prescription Drug Spending.  They show the increasing price of U.S. prescription drugs spending over time. They also show that many patients with Medicare Part D, still bear a large share of prescription drug costs for […]

Read the rest of this entry »

Gates: US Drug pricing system is ‘Better Than Most’

There has been a lot of criticism of drug prices in the U.S. One person not included the chorus of critics is Bill Gates. In an interview with Bloomberg, he said: “The current system is better than most other systems one can imagine,” Gates said in an interview on Bloomberg Television. “The drug companies are […]

Read the rest of this entry »

After 190 failed tries…

Why are pharmaceuticals so expensive?  One reasons is that there is a lot of research that goes into developing a drug.  Most of that research results in drugs that don’t work.  One example is the search for Alzheimer’s treatment.  As Bloomberg reports: Drug companies have long focused on a different protein called amyloid that clumps in […]

Read the rest of this entry »

Brexit = upheaval for drug makers

Will the European Medicines Agency (EMA) need to re-located after Brexit? According to a Reuters story, the answer is yes. The EMA is a London-based organization that approves treatments for all EU countries. As the UK leaves the EU, however, EMA is expected to have to relocate. 600 individuals work for EMA. More important is […]

Read the rest of this entry »

ICER and drug prices

The Institute for Clinical and Economic Research aims to measure the value of drugs and aims to reduce the price of treatments that they deem to be low-value.  Is this simply an academic exercises, or are payers paying attention?  An article in CNBC sheds some light on the topic: Asked about that analysis, Miller said: “We […]

Read the rest of this entry »

Medicaid Managed Care and Drug Utilization for Patients with Serious Mental Illness

How will Medicaid expansions affect patient access to pharamceuticals? This question is particularly relevant for patients with serious mental illness. The answer is complicated by the increasing presence of Medicaid managed care plans. Increasingly, states have turned to contracts with Medicaid managed care plans in order to better control costs and reduce budgetary uncertainty. However, in […]

Read the rest of this entry »

Money back guarantee

With increasing pressure on the price of health care services, a number of firms are seeking innovative pricing strategies.  Stat reports: Stryker, a medical device company, developed its SurgiCount system to accurately track these sponges. This March, it announced it is backing the product with a $5 million guarantee. If the system is used as […]

Read the rest of this entry »